$16.5 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$89.65 - $159.54The lowest and highst price in the last 52 weeks.
-19.13xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$16.5 Billion|
|Enterprise Value||$17.4 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||-3.4%|
|Outstanding Shares||172 Million|
|Avg 30 Day Volume||1.34 Million|
|Earnings per Share||-$5.34|
|Price to Sales Ratio||10.44|
|Price to Book Ratio||4.7|
|Revenue to Enterprise Value||10.19|
|EBIT to Enterprise Value||-19.79|
|Total Debt to Enterprise Value||0.13|
|Debt to Equity||0.62|
|Gross Profit||$1.29 Billion|
|Net Income||-$865 Million|
|Quarterly Earnings Growth (YoY)||+105.4%|
|Return on Equity||-24.3%|
|Return on Assets||-12.86%|
|Return on Invested Capital||-14.57%|
204,580 shares sold (29 transactions)
54,379 shares sold (3 transactions)
52,001 shares sold (6 transactions)
CEO: Kevin Conroy
Industry: Research and Development in Biotechnology
Equities research analysts expect Exact Sciences Co. (NASDAQ:EXAS) to announce $429.04 million in sales for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Exact S...Dakota Financial News, about 20 hours ago
Two blood tests made by Exact Sciences and Illumina that aim to pinpoint early signs of cancer are launching in the US.Business Insider, 4 days ago
No summary available.Insider Monkey, 12 days ago